Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer [0.03%]
靶向SLC7A11介导的半胱氨酸代谢以治疗曲妥珠单抗耐药性HER2阳性乳腺癌
Yijia Hua,Ningjun Duan,Chunxiao Sun et al.
Yijia Hua et al.
Trastuzumab resistance remains a challenge for HER2-positive breast cancer treatment. Targeting metabolic reprogramming would provide novel insights for therapeutic strategies. Here, we integrated metabolomics, transcriptomics, and epigenom...
PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer [0.03%]
帕金5通过增加人表皮生长因子受体2阳性乳腺癌细胞核内的人表皮生长因子受体2累积来促进曲妥珠单抗耐药性
Xin Zhao,Yang Li,Hongyan Zhang et al.
Xin Zhao et al.
Nuclear HER2 (N-HER2) predicts resistance to HER2-targeted therapy and poor prognosis of breast cancer patients, and the underlying mechanisms remain unclear. Here, we show that high expression of p21-activated kinase 5 (PAK5) is associated...
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer [0.03%]
关于CMTM6过表达介导赫尔赛阳性乳腺癌曲妥珠单抗耐药的更正通知
Fei Xing,Hongli Gao,Guanglei Chen et al.
Fei Xing et al.
Published Erratum
Molecular cancer. 2025 Apr 14;24(1):115. DOI:10.1186/s12943-025-02317-7 2025
An antibody-photosensitiser bioconjugate overcomes trastuzumab resistance in HER2-positive breast cancer [0.03%]
抗体光敏生物偶联物克服了HER2阳性乳腺癌中的曲妥珠单抗耐药性
Mireia Jordà-Redondo,Ana Piqueras,Ana Castillo et al.
Mireia Jordà-Redondo et al.
HER2-positive breast cancer, characterized by the overexpression of HER2 receptors, often develops resistance to trastuzumab, limiting its therapeutic efficacy. In this study, we explore the use of photodynamic therapy (PDT) with a trastuzu...
Pyrotinib monotherapy for advanced HER2-positive esophageal adenocarcinoma with trastuzumab resistance and chemotherapy intolerance: a case report and literature review [0.03%]
曲妥珠单抗耐药及化疗不耐受的晚期HER2阳性食管腺癌患者接受吡咯替尼单药治疗一例并文献复习
Tao Wang,Mingyuan He,Wei Guan
Tao Wang
HER2-positive advanced esophageal adenocarcinoma (EAC) cases demonstrate a poor prognosis because of drug resistance that develops after standard first-line trastuzumab therapy. The patient was initially diagnosed with stage cT2N1M0 III EAC...
Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing [0.03%]
胆囊癌全长转录组图谱揭示了由ERBB2可变剪接引起的曲妥珠单抗耐药性
Ziyi Wang,Li Gao,Ziheng Jia et al.
Ziyi Wang et al.
Aberrant RNA alternative splicing in cancer generates varied novel isoforms and protein variants that facilitate cancer progression. Here, we employed the advanced long-read full-length transcriptome sequencing on gallbladder normal tissues...
Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan [0.03%]
抗HER2阳性乳腺癌和胃癌曲妥珠单抗恩赫汀和德鲁替康耐药的小鼠模型中的Disitamab vedotin研究
Negar Pourjamal,Vadim Le Joncour,György Vereb et al.
Negar Pourjamal et al.
Background: Most HER2-positive breast or gastric cancers eventually become resistant to the approved anti-HER2 antibody-drug conjugates (ADC) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd). Disitamab ved...
Corrigendum to "LncRNA ZNF649-AS1 promotes trastuzumab resistance and TAM-dependent PD-L1 expression in breast cancer by regulating EXOC7 alternative splicing" [Archiv. Biochem. Biophys. 761 (2024) 110128] [0.03%]
关于“长链非编码RNA ZNF649-AS1通过调节EXOC7剪接变体促进乳腺癌曲妥珠单抗耐药和巨噬细胞依赖性PD-L1表达”的勘误 [Archiv. Biochem. Biophys. 761 (2024) 110128]
Huaying Dong,Jing Han,Xiang Chen et al.
Huaying Dong et al.
Published Erratum
Archives of biochemistry and biophysics. 2024 Dec 10:110220. DOI:10.1016/j.abb.2024.110220 2024
Overcoming resistance in HER2-positive gastric cancer: a case report on the synergistic effect of pembrolizumab and trastuzumab [0.03%]
克服HER2阳性胃癌的耐药性：帕博利珠单抗与曲妥珠单抗协同作用的一例报告
Ting Gong,Qing Ma,Yaoyao Ren et al.
Ting Gong et al.
Introduction: The first-line standard therapy for advanced HER2-positive gastric cancer is chemotherapy combined with trastuzumab and pembrolizumab, while pembrolizumab alone does not benefit as a monotherapy in patients ...
耗时 0.10376 秒，为您在
48285708
条记录里面共找到 292 篇文章 [XML]